These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 37998380)

  • 1. Elucidation of GPR55-Associated Signaling behind THC and LPI Reducing Effects on Ki67-Immunoreactive Nuclei in Patient-Derived Glioblastoma Cells.
    Kolbe MR; Hohmann T; Hohmann U; Maronde E; Golbik R; Prell J; Illert J; Strauss C; Dehghani F
    Cells; 2023 Nov; 12(22):. PubMed ID: 37998380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. THC Reduces Ki67-Immunoreactive Cells Derived from Human Primary Glioblastoma in a GPR55-Dependent Manner.
    Kolbe MR; Hohmann T; Hohmann U; Ghadban C; Mackie K; Zöller C; Prell J; Illert J; Strauss C; Dehghani F
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33802282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lysophosphatidylinositol causes neurite retraction via GPR55, G13 and RhoA in PC12 cells.
    Obara Y; Ueno S; Yanagihata Y; Nakahata N
    PLoS One; 2011; 6(8):e24284. PubMed ID: 21904624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GPR55, a lysophosphatidylinositol receptor with cannabinoid sensitivity?
    Nevalainen T; Irving AJ
    Curr Top Med Chem; 2010; 10(8):799-813. PubMed ID: 20370712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids.
    Anavi-Goffer S; Baillie G; Irving AJ; Gertsch J; Greig IR; Pertwee RG; Ross RA
    J Biol Chem; 2012 Jan; 287(1):91-104. PubMed ID: 22027819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different receptor mechanisms underlying phytocannabinoid- versus synthetic cannabinoid-induced tetrad effects: Opposite roles of CB
    Wang XF; Galaj E; Bi GH; Zhang C; He Y; Zhan J; Bauman MH; Gardner EL; Xi ZX
    Br J Pharmacol; 2020 Apr; 177(8):1865-1880. PubMed ID: 31877572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysophosphatidylinositol Induced Morphological Changes and Stress Fiber Formation through the GPR55-RhoA-ROCK Pathway.
    Nakajima K; Oka S; Tanikawa T; Nemoto-Sasaki Y; Matsumoto N; Ishiguro H; Arata Y; Sugiura T; Yamashita A
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The G protein-coupled receptor 55 ligand l-α-lysophosphatidylinositol exerts microglia-dependent neuroprotection after excitotoxic lesion.
    Kallendrusch S; Kremzow S; Nowicki M; Grabiec U; Winkelmann R; Benz A; Kraft R; Bechmann I; Dehghani F; Koch M
    Glia; 2013 Nov; 61(11):1822-31. PubMed ID: 24038453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The oncogenic lysophosphatidylinositol (LPI)/GPR55 signaling.
    Calvillo-Robledo A; Cervantes-Villagrana RD; Morales P; Marichal-Cancino BA
    Life Sci; 2022 Jul; 301():120596. PubMed ID: 35500681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function.
    Kargl J; Brown AJ; Andersen L; Dorn G; Schicho R; Waldhoer M; Heinemann A
    J Pharmacol Exp Ther; 2013 Jul; 346(1):54-66. PubMed ID: 23639801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What is the natural ligand of GPR55?
    Okuno T; Yokomizo T
    J Biochem; 2011 May; 149(5):495-7. PubMed ID: 21324983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lysophosphatidylinositol induces rapid phosphorylation of p38 mitogen-activated protein kinase and activating transcription factor 2 in HEK293 cells expressing GPR55 and IM-9 lymphoblastoid cells.
    Oka S; Kimura S; Toshida T; Ota R; Yamashita A; Sugiura T
    J Biochem; 2010 May; 147(5):671-8. PubMed ID: 20051382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The actions and metabolism of lysophosphatidylinositol, an endogenous agonist for GPR55.
    Yamashita A; Oka S; Tanikawa T; Hayashi Y; Nemoto-Sasaki Y; Sugiura T
    Prostaglandins Other Lipid Mediat; 2013 Dec; 107():103-16. PubMed ID: 23714700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological characterization of GPR55, a putative cannabinoid receptor.
    Sharir H; Abood ME
    Pharmacol Ther; 2010 Jun; 126(3):301-13. PubMed ID: 20298715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysophosphatidylinositol Promotes Chemotaxis and Cytokine Synthesis in Mast Cells with Differential Participation of GPR55 and CB2 Receptors.
    Martínez-Aguilar LM; Ibarra-Sánchez A; Guerrero-Morán DJ; Macías-Silva M; Muñoz-Bello JO; Padilla A; Lizano M; González-Espinosa C
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GPR55 - a putative "type 3" cannabinoid receptor in inflammation.
    Yang H; Zhou J; Lehmann C
    J Basic Clin Physiol Pharmacol; 2016 May; 27(3):297-302. PubMed ID: 26669245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GPR55 ligands promote receptor coupling to multiple signalling pathways.
    Henstridge CM; Balenga NA; Schröder R; Kargl JK; Platzer W; Martini L; Arthur S; Penman J; Whistler JL; Kostenis E; Waldhoer M; Irving AJ
    Br J Pharmacol; 2010 Jun; 160(3):604-14. PubMed ID: 20136841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The GPR55 agonist lysophosphatidylinositol relaxes rat mesenteric resistance artery and induces Ca(2+) release in rat mesenteric artery endothelial cells.
    AlSuleimani YM; Hiley CR
    Br J Pharmacol; 2015 Jun; 172(12):3043-57. PubMed ID: 25652040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Mechanisms of GPR55 Receptor Functional Selectivity during Apoptosis and Proliferation Regulation in Cancer Cells.
    Akimov MG; Gretskaya NM; Dudina PV; Sherstyanykh GD; Zinchenko GN; Serova OV; Degtyaryova KO; Deyev IE; Bezuglov VV
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GPR55-mediated effects on brain microvascular endothelial cells and the blood-brain barrier.
    Leo LM; Familusi B; Hoang M; Smith R; Lindenau K; Sporici KT; Brailoiu E; Abood ME; Brailoiu GC
    Neuroscience; 2019 Aug; 414():88-98. PubMed ID: 31279825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.